And administration of 8-Br-cADPR (a competitive CD38 enzyme hydrolysate inhibitor) could result in a significant inhibition of cell proliferation, colony formation, and migration on CD38 WT and OE tumor cells, but not on CD38 KO and MU cells (Fig. 3B, C, E, Fig. S3D). The gene discussed is CD38; the disease is neoplasm.